Erythropoiesis and neuroprotection: Two sides of the same coin?

Lancet Neurology

Volumn 2, Issue 6, 2003, Pages 332-

  Grasso, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; HYPOXIA INDUCIBLE FACTOR 1; JANUS KINASE 2; RECOMBINANT ERYTHROPOIETIN;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; BRAIN VASOSPASM; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SAFETY; ERYTHROPOIESIS; GENE EXPRESSION REGULATION; HUMAN; MEDICAL ASSESSMENT; MOLECULAR CLONING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT SURVEY; STROKE;

EID: 12144289049     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00403-4     Document Type: Letter

References (5)

1. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 88:2000;1474-1480.
2. Grasso G., Buemi M., Alafaci C., et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA. 99:2002;5627-5631.
3. Digicaylioglu M., Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 412:2001;641-647.
4. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 8:2002;495-505.
5. Amgen I. Epogen (epoetin alfa) prescribing information. Physicians' Desk Reference. 54th edn:2000;Medical Economics Press, Montvale.